Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Phase 1 Completed 128 enrolled Arbutus Biopharma Corporation

RandomizedParallel-groupSingle-blindTreatment

Summary

This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

Timeline

Start: 2023-08-30
Primary completion: 2025-12-04
Completion: 2026-02-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AB-101	Cell therapy	—	Oral

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Summary

Timeline

Drugs

Indications